Report Overview

Indian Alzheimer Drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

In India, more than 4 million people are estimated to be suffering from Alzheimer and other forms of dementia, giving the country the third highest caseload. Alzheimers disease is one of the most common form of dementia which is characterized by progressive degeneration of cognitive abilities. It has symptoms like forgetting things in the early stages to loss of speech and immobility in its late stages. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning.



Market Drivers

Increasing awareness of among the Indian population and Indian physicians, investments in Indias healthcare infrastructure will result in increasing accessibility, growing elderly population. On the other hand, growing demand for personalized drugs and affordable diagnostics tests will further boost various opportunities that will lead to the growth of the Alzheimers disease drugs market. The advancement of diagnostics equipment increases the lifespan of this demographic and improves the quality of life for those suffering from neurological conditions. Hence, the presence of a large geriatric population pool is considered a vital driver for this industry.